A theranostic probe of indoleamine 2,3-dioxygenase 1 (IDO1) for small molecule cancer immunotherapy

Ying Wu,Yanhui Zhang,Xi Chen,Yulu Hu,Guoqiang Dong,Yuan Guo,Chunquan Sheng
DOI: https://doi.org/10.1016/j.ejmech.2021.113163
IF: 7.088
2021-03-01
European Journal of Medicinal Chemistry
Abstract:<p>Discovering novel small molecules for cancer immunotherapy represents a promising but challenging strategy in future cancer treatment. Herein, we designed the first theranostic fluorescent probes to efficiently detect and inhibit the enzymatic activity of 2,3-dioxygenase 1 (IDO1). Probe <strong>6b</strong> is a highly active IDO1 inhibitor (IC<sub>50</sub> = 12 nM, Cellular IC<sub>50</sub> = 10 nM), which can sensitively and specifically detect endogenous IDO1 in living cells. Furthermore, as a theranostic probe, <strong>6b</strong> showed excellent <em>in vivo</em> antitumor efficacy in the CT26 xenograft mouse model as well. Therefore, it can be applied as a valuable chemical tool for better understanding the immunotherapy mechanism of IDO1 and improving the therapeutic efficiency.</p>
chemistry, medicinal
What problem does this paper attempt to address?